Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area
Conditions: Onchocerciasis; Epilepsy Intervention: Drug: Bi-annual CDTI Sponsor: Universiteit Antwerpen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2023 Category: Research Source Type: clinical trials
Emodepside Phase II Trial for Treatment of Onchocerciasis
Condition: Onchocerciasis Interventions: Drug: emodepside; Drug: matching placebo of emodepside; Drug: ivermectin; Drug: matching placebo of ivermectin Sponsors: Drugs for Neglected Diseases; Bayer Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2022 Category: Research Source Type: clinical trials
Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug
Conditions: Filariasis, Lymphatic; Onchocerciasis Interventions: Drug: AWZ1066S; Drug: Placebo Sponsors: Liverpool School of Tropical Medicine; Liverpool University Hospitals NHS Foundation Trust; Covance; Subiaco Associates Limited; Sylexis Limited; Eisai Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2021 Category: Research Source Type: clinical trials
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection
Condition: Onchocerciasis Interventions: Drug: ABBV-4083; Drug: Placebo for ABBV-4083; Drug: Albendazole; Drug: Placebo for Albendazole; Drug: Placebo for Ivermectin; Drug: Ivermectin Sponsors: AbbVie; Drugs for Neglected Diseases initiative Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 4, 2021 Category: Research Source Type: clinical trials
